Sony Xperia Tablet Z goes up for pre

Sony originally announced the tablets for sale Xperia Tablet Z in January, but at the time it was only headed to Japan. Fast forward to Mobile World Congress at the end of February, and the company used its press conference to inform us the tablet would be making its debut internationally during the spring.

That time has now come, as the Xperia Tablet Z has been made available as a pre-order through Sony’s own online store in the UK. Quite apart from being able to grab one of the tablets for yourself, this is the first time the price has been revealed. Only the Wi-Fi models are currently on sale, with the 16GB Xperia Tablet Z priced at £400 ($605), or if you spend another £50 you’ll get the 32GB model.

For this you get a 10.1-inch display with a 1920 x 1200 pixel resolution, a quad-core Snapdragon S4 Pro processor, 2GB of RAM, an 8-megapixel rear camera, 7 inch tablet and Android 4.1 Jelly Bean. When we spent some time with the Xperia Tablet Z at MWC, we were particularly impressed with its design, and loved the lightweight, super-slim (just 6.9mm) chassis, which was a joy to hold.

When you go to buy one of the tablets, you’re given the option of selecting a range of accessories, including a £60 ($90) leather cover, £30 ($45) docking station and a £15 ($22) screen protector. Once the tablet is in your basket, the site provides a delivery date of 21sQW1F2 between April 12 and April 15.

So how does the Xperia Tablet Z’s price compare with other tablets on sale in the UK? Well, the 16GB model matches the basic iPad, but the 32GB Tablet Z is £30 less expensive than the equivalent Apple tablet. A tablets for sale Samsung Galaxy Note 10.1 with 16GB of storage memory is also £400, while the 16GB Nexus 10 (which has a higher screen resolution than Sony’s tablet) can be purchased through Google Play for £320.

Abstral is a new treatment option for inadequately controlled breakthrough cancer pain, or BTcP, in patients who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. Abstral provides rapid relief of BTcP, predictable dosing, and is convenient and easy to use. Abstral was approved by the U.S. FDA in January 2011.